Blaze Bioscience is a biotechnology company focused on improving the lives of cancer patients through innovative technologies. Founded in 2010 by Dr. Jim Olson and Heather Franklin, the company is pioneering the development of Tumor Paint products, which are designed to improve the precision of cancer surgeries. Tumor Paint technology helps surgeons visualize cancerous tissues in real-time during operations, thereby enhancing the accuracy of tumor removal and minimizing damage to healthy tissues. Blaze Bioscience primarily serves medical professionals and healthcare institutions specializing in oncology and neurosurgery. Operating in the biotechnology and medical device markets, the company generates revenue through the development and commercialization of its proprietary Tumor Paint products, including its lead candidate, BLZ 100. The business model involves advancing these products through clinical trials and obtaining regulatory approvals to bring them to market. Blaze Bioscience aims to revolutionize cancer surgery and improve patient outcomes by providing cutting-edge intraoperative imaging solutions.

Keywords: Tumor Paint, cancer surgery, intraoperative imaging, biotechnology, BLZ 100, oncology, neurosurgery, clinical trials, regulatory approvals, healthcare innovation.